REGENTIS BIOMATERIALS LTD.

Regentis Biomaterials (RGNT) has shown no cyber incidents or material red-flag 8-K filings in our 90-day monitoring window. However, low signal in this timeframe doesn't indicate absence of risk—the company operates in a capital-intensive biotech sector where financing activities and equity dilution require deeper historical context. The full $49 Report extends analysis to 12 months of SEC filings, calculates dilution risk scores, and maps financing history alongside AI-detected risk signals across officer changes and operational shifts. The full $49 Report adds quantified dilution exposure, 12-month 8-K filing context, and sector-specific capital structure risk assessment.